Catalyst

Slingshot members are tracking this event:

Insmed (INSM) Expects to Begin Phase 2 Dose-Ranging Study in 2017 Evaluating AstraZeneca's (AZN) AZD7986 in Non-Cystic Fibrosis Bronchiectasis

Source Link:
http://files.shareholder.com/downloads/INSMED/2964432481x0x910600/FB95128D-52B7-47C0-A0BB-1AE9BE55AB79/INSM_News_2016_10_5_General.pdf

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AZN
100%
INSM
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Jul 17, 2017
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT03218917
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2 Dose-ranging Study, Non-cystic Fibrosis Bronchiectasis, Azd7986
About Us
Media Center
Connect with Us
© 2025 Slingshot Insights. All rights reserved.